UBS Group’s Cellyan Biotechnology HKPD Stock Holding History

UBS Group’s Portfolio HKPD Stock Details HKPD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-54	Closed	-$411	–	11841
2026 Q2	$411	Buy	54 +48	+800%	+$526	﹤0.01%	9865
2026 Q1	$63	Sell	6 -71	-92%	-$1.03K	﹤0.01%	10179
2025 Q4	$1.27K	Buy	77 +72	+1,440%	+$1.54K	﹤0.01%	9645
2025 Q3	$144	Sell	5 -1,039	-100%	-$26.6K	﹤0.01%	9870
2025 Q2	$26.7K	Buy	1,044 +1,030	+7,357%	+$25.5K	﹤0.01%	8248
2025 Q1	$294	Buy	+14	New	+$494	﹤0.01%	9847

Other funds holding HKPD

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group's HKPD Position: Q3 2026 in Review

UBS Group sold out of Cellyan Biotechnology (HKPD) in Q3 2026, closing a stake of 54 shares — an estimated $411 sold.

UBS Group first reported a position in HKPD in Q1 2025 and held it in 6 quarters. The position peaked at $26.7K in Q2 2025. 1 fund tracked by Wall St. Rank holds HKPD as of Q3 2026.

UBS Group reported no remaining Cellyan Biotechnology position as of Q3 2026 after selling out during the quarter.
UBS Group sold 54 Cellyan Biotechnology shares in Q3 2026, an estimated $411.
UBS Group first reported a position in Cellyan Biotechnology in Q1 2025 and held it in 6 quarters.
UBS Group's Cellyan Biotechnology position peaked at $26.7K in Q2 2025.
1 fund tracked by Wall St. Rank held Cellyan Biotechnology as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.